Celecoxib and omega-3 fatty acids alone and in combination with risperidone affect the behavior and brain biochemistry in amphetamine-induced model of schizophrenia

El‐Sisi, Alaa E.; Sokkar, Samia Salem; El-Sayad, Magda El-Sayed; Ramadan, Ehab Sayed; Osman, Enass Yossef

doi:10.1016/j.biopha.2016.05.024

Cited by 28 publications

(22 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In pre-clinical dietary n-3 PUFAs deficiency, an important decrease of DHA brain content was shown to alter DA function in a manner comparable to that reported in SCZ patients [132,133]. Likewise, in a pre-clinical model of amphetamine-induced SCZ-like behavior, n-3 PUFAs dietary supplementation reduced behavioral deficits, cytokine release and enhanced the effects of combined antipsychotic and celecoxib drug treatment [134]. Since brain DHA deficiency may alter the expression of DA receptors in ventral striatum and contribute to hypofunctioning of mesolimbic DA system and anhedonia as observed in depression [22,[135][136][137], then prenatal or early postnatal deficits of brain n-3 PUFAs status may be a pivotal factor in depression pathogenesis.…”

Section: N-3 Pufas Serotonin Dopamine and Npdssupporting

confidence: 53%

Dietary Fatty Acids and Microbiota-Brain Communication in Neuropsychiatric Diseases

Marrone

Coccurello

2019

Biomolecules

View full text Add to dashboard Cite

The gut-brain axis is a multimodal communication system along which immune, metabolic, autonomic, endocrine and enteric nervous signals can shape host physiology and determine liability, development and progression of a vast number of human diseases. Here, we broadly discussed the current knowledge about the either beneficial or deleterious impact of dietary fatty acids on microbiota-brain communication (MBC), and the multiple mechanisms by which different types of lipids can modify gut microbial ecosystem and contribute to the pathophysiology of major neuropsychiatric diseases (NPDs), such as schizophrenia (SCZ), depression and autism spectrum disorders (ASD).

show abstract

Section: N-3 Pufas Serotonin Dopamine and Npdssupporting

confidence: 53%

Dietary Fatty Acids and Microbiota-Brain Communication in Neuropsychiatric Diseases

Marrone

Coccurello

2019

Biomolecules

View full text Add to dashboard Cite

show abstract

“…[ 128 ] An amphetamine‐induced rat model of SCZ presented behavioral deficits including impaired performance in the Morris water maze, Y‐maze, and social recognition tasks, which were attenuated by omega‐3 PUFAs. [ 129 ] Cuprizone‐induced demyelination models white matter abnormality in SCZ. [ 130 ] NAC could reverse the cognitive deficits and neurochemical deficits in the Cuprizone‐induced SCZ mouse model.…”

Section: Mitochondrial Function As a Potential Therapeutic Target Formentioning

confidence: 99%

Mitochondrial Dysfunction in Schizophrenia

Chung

2020

BioEssays

View full text Add to dashboard Cite

Schizophrenia (SCZ) is a severe neurodevelopmental disorder affecting 1% of populations worldwide with a grave disability and socioeconomic burden. Current antipsychotic medications are effective treatments for positive symptoms, but poorly address negative symptoms and cognitive symptoms, warranting the development of better treatment options. Further understanding of SCZ pathogenesis is critical in these endeavors. Accumulating evidence has pointed to the role of mitochondria and metabolic dysregulation in SCZ pathogenesis. This review critically summarizes recent studies associating a compromised mitochondrial function with people with SCZ, including postmortem studies, imaging studies, genetic studies, and induced pluripotent stem cell studies. This review also discusses animal models with mitochondrial dysfunction resulting in SCZ-relevant neurobehavioral abnormalities, as well as restoration of mitochondrial function as potential therapeutic targets. Further understanding of mitochondrial dysfunction in SCZ may open the door to develop novel therapeutic strategies that can address the symptoms that cannot be adequately addressed by current antipsychotics alone.

show abstract

“…Preclinical studies have provided evidence for a potential therapeutic role of anti-inflammatory agents in the treatment of schizophrenia; however, the reliability of behavioral alterations induced by psychomimetic drugs in animal models is limited compared with psychotic symptoms manifested in humans. El-Sayed El-Sisi et al [64] showed a significant therapeutic effect of celecoxib, a well-known anti-inflammatory agent that selectively inhibits cyclooxygenase (COX)-2, using the amphetamine-induced model in rats [64]. Combined administration of celecoxib with risperidone reversed behavioral impairments induced by amphetamine and reduced TNF- levels in the rat brain.…”

Section: Preclinical Studies Of the Therapeutic Effects Of Anti-inflamentioning

confidence: 99%

Anti-inflammatory Strategies for Schizophrenia: A Review of Evidence for Therapeutic Applications and Drug Repurposing

Hong

Bang

2020

Clin Psychopharmacol Neurosci

View full text Add to dashboard Cite

Schizophrenia is a debilitating psychiatric disorder with a substantial socioeconomic and humanistic burden. Currently available treatment strategies mostly rely on antipsychotic drugs, which block dopaminergic effects in the mesolimbic pathway of the brain. Although antipsychotic drugs help relieve psychotic symptoms, a definitive cure for schizophrenia has yet to be achieved. Recent advances in neuroinflammation research suggest that proinflammatory processes in the brain could cause alterations in neurobehavioral development and increase vulnerability to schizophrenia. With a growing need for novel strategies in the treatment of schizophrenia, it would be meaningful to review the current evidence supporting the therapeutic potential of anti-inflammatory strategies. This review details the key findings of clinical trials that investigate the efficacy of anti-inflammatory agents as adjuvants to antipsychotic treatment. We further discuss the possibilities of repurposing anti-inflammatory agents and developing novel strategies for the treatment of schizophrenia.

show abstract

Celecoxib and omega-3 fatty acids alone and in combination with risperidone affect the behavior and brain biochemistry in amphetamine-induced model of schizophrenia

Cited by 28 publications

References 54 publications

Dietary Fatty Acids and Microbiota-Brain Communication in Neuropsychiatric Diseases

Dietary Fatty Acids and Microbiota-Brain Communication in Neuropsychiatric Diseases

Mitochondrial Dysfunction in Schizophrenia

Anti-inflammatory Strategies for Schizophrenia: A Review of Evidence for Therapeutic Applications and Drug Repurposing

Contact Info

Product

Resources

About